Amgen beats on both lines in Q4 and issues 2026 guidance
Amgen’s (AMGN) Q4 2025 results beat on both lines as the biotech issued 2026 financial guidance with revenue and EPS ranges that both include the consensus figure.
In 2026, Amgen is expecting revenue of $37B-$38.4B. Consensus is $37.02B. Non-GAAP EPS is projected at $21.60-$23.00. Consensus
